Cellectar Biosciences (CLRB) Stock: Gaining On Positive Clinical Data

Cellectar Biosciences Inc (NASDAQ: CLRB) is having an overwhelmingly strong day in the market today, and for good reason. The company released overwhelmingly positive news with regard to CLR 131. Of course, this led to excitement among investors, causing gains and prompting our friends at Trade Ideas to alert us to the movement. Currently (9:57), … Read more

Cellectar Biosciences (CLRB) Stock: This Collaboration Could Be Huge!

Cellectar Biosciences Inc (NASDAQ: CLRB) is one to put on your watch list as huge news was recently released. Yesterday, the company released a PR informing investors of a key collaboration with Avicenna Oncology. CLRB Enters Into A Collaboration Agreement With Avicenna Oncology As mentioned above, Cellectar Biosciences is having a relatively strong start to … Read more

Cellactar Biosciences (CLRB) Stock Climbs On Multiple Myeloma Trial Update

Cellectar Biosciences Inc (NASDAQ: CLRB) Cellectar Biosciences, on Monday, reported additional data related to its on-going Phase I clinical trial of CLR-131 in multiple myeloma. The report highlighted the successful completion of its third cohort and initiation of Cohort 4 treatment at an increased dose of 31.25 mCi/m2 dose. Strong Results Lead To CLR 131 Dosing … Read more

Cellectar Biosciences (CLRB) Stock: Skyrocketing On Trial Update

Cellectar Biosciences Inc (NASDAQ: CLRB) Cellectar Biosciences is likely to have an incredibly strong day in the market today considering the gains we’re seeing in the pre-market. After releasing an update surrounding a Phase 1 clinical trial, the stock is soaring. Below, we’ll talk about what we’re seeing, why, and what we’ll be watching for … Read more

Cellectar Biosciences (CLRB) Stock: Gaining On Positive Study Announcement

Cellectar Biosciences Inc (NASDAQ: CLRB) While it is early on in the market at the moment, that’s not stopping Cellectar Biosciences from seeing gains. At the open of the trading session, the stock was already trading well in the green. The gains are the result of an announcement surrounding a key Phase 1 clinical trial. … Read more

Cellectar Biosciences (CLRB) PDC Delivery Platform May Advance Treatment of Multiple Myeloma

Cellectar Biosciences Inc (NASDAQ: CLRB) Cellectar Biosciences is a Madison, WI based oncology company that is generating a tremendous amount of industry interest, with an increasing amount of attention being placed on the company’s Phosphopipid Drug Conjugate (PDC), a proprietary platform that enables delivery of diverse oncologic payloads through its phospholipid ether cancer-targeting vehicle. Importantly, not … Read more

Cellectar Biosciences (CLRB) is Oversold And Ready To Bounce Higher

Cellectar Biosciences Inc (NASDAQ: CLRB) Cellectar Biosciences is an oncology focused company based in Madison, Wisconsin. Since the beginning of the year, CLRB has been trading down significantly from its 52-week high of $18.00 per share, closing at $1.77 during Thursday’s trading session. However, investors appear to have liked what they heard during the earnings release … Read more